Skip to main content
Equibles

Jonathan Pachter

Verastem, Inc. (VSTM)

Equibles does not estimate personal net worth.

Get an email with a short summary when Verastem, Inc. publishes a filing, an earnings call transcript or a press release.

Get VSTM alerts

About Jonathan Pachter

Jonathan Pachter has spoken on 2 investor events across 1 company, most recently for Verastem, Inc. on June 23, 2026. Verastem, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Verastem, Inc. includes Brian M. Stuglik (CEO), Daniel Paterson (CEO and Board Member), Michael Bailey (CEO) and 7 others.

Jonathan Pachter on recent calls

“Now, I'll hand it over to john to give you a sense of the future potential combinations to improve patient outcomes john thanks michael vs 7 375 is optimized with several properties that make it the potential best-in-class ras inhibitor for treatment of patients with kras g12d mutated cancers as dan outlined earlier…”
Other, Verastem Oncology VS-7375 TARGET-D Conference Call ·
“It's a very exciting time for Veristim Oncology. We're a commercial-stage multi-asset company focused on small-molecule oral drugs targeting Rasmap kinase pathway-driven cancers.”
Other, Jefferies Global Healthcare Conference ·

Affiliation history

Company network

Leadership on record at Verastem, Inc.

Recent activity